Abstract
Four new binuclear Ru(II)-arene complexes with N-ferrocenyl amino acid ligands and 4,4′-azopyridine as the bridging group [(p-cym)(Fc-AA)Ru(μ-azpy)Ru(Fc-AA)(p-cym)]Cl (C1–C4; where p-cym = p-cymene, MeC6H4Pri; Fc-AA = N-ferrocenyl amino acid conjugate ligands (Fc-tyr 1, Fc-phe 2, Fc-leu 3, Fc-trp 4) and azpy = 4,4′-azopyridine) were synthesized and characterized by 1H NMR, UV—visible, FTIR and mass spectroscopy, and CHN analysis. The structure of one of the precursor mononuclear complexes, [(p-cym)Ru(Fc-phe)Cl], was determined by single-crystal X-ray diffraction studies. Binding of the complexes with calf-thymus DNA and bovine serum albumin (BSA) has been evaluated using absorption and emission spectral studies. Ethidium bromide-displacement studies and DNA-viscosity measurements affirmed intercalative interaction mode between complexes and CT-DNA. Fluorescence titration was used to explore interaction of the complexes with BSA. MTT assay was adopted to evaluate the anticancer activity of C1–C4 on HeLa cell line and the corresponding IC50 values were calculated. The IC50 values of the complexes were higher than that for cisplatin but much lower than for NAMIA and RAPTA-C. The lower cytotoxicity of C1–C4 compared to cisplatin is explained based on nucleotide excision repair mechanism.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
